Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992668 | 0.86 | MAPK1 (0.40) | MAPK1PDGFRBKDRCNR2L3MBTL1 | |
| SCHEMBL5142651 | 0.77 | CNR2 (0.37) | CNR2L3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL3530577 | 0.71 | MAPT (0.48) | MAPK1PDGFRBKDRKMT2ANPC1 | |
| SCHEMBL5142650 | 0.70 | CNR2 (0.38) | CNR2KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL2249696 | 0.68 | PDGFRB (0.47) | PDGFRBKDRKMT2ANPC1RAB9A | |
| SCHEMBL30539315 | 0.66 | KMT2A (0.59) | L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL7821841 | 0.66 | KMT2A (0.59) | L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL19151139 | 0.65 | ALDH1A1 (0.48) | KMT2AMEN1LMNAPOLB | |
| SCHEMBL4982513 | 0.65 | L3MBTL1 (0.46) | CNR2L3MBTL1 | |
| SCHEMBL4988108 | 0.65 | GPR183 (0.36) | CNR2KMT2AMEN1LMNAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | MAPK1 546/4885PDGFRB 1740/4885KDR 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.